Schrodinger, Inc. (SDGR) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K
Revenues:
Software Segment	113.2	92.5	66.7
Drug Discovery Segment	24.7	15.6	18.8
Total revenues	137.9	108.1	85.5	85.5
Revenue growth [+]	27.6%	26.4%	0.0%
Software Segment	22.4%	38.7%
Drug Discovery Segment	58.7%	-17.2%
Rest of World	32.4%	39.3%
Cost of goods sold	72.3	44.6	36.5	36.5
Gross profit	65.6	63.5	49.1	49.1
Gross margin	47.6%	58.7%	57.4%	57.4%
Selling, general and administrative [+]	86.2	59.7	48.4	48.4
Sales and marketing	22.2	17.8	21.4	21.4
General and administrative	64.0	41.9	27.0	27.0
Research and development	90.9	64.7	39.4	39.4
Equity in earnings	-1.8	4.1	0.9
EBITDA [+]	-110.4	-53.2	-34.1	-35.1
EBITDA growth	107.7%	55.7%	-2.7%
EBITDA margin	-80.0%	-49.2%	-39.9%	-41.0%
Depreciation and amortization	2.8	3.7	3.6	3.6
EBIT [+]	-113.2	-56.8	-37.8	-38.7
EBIT growth	99.3%	50.4%	-2.4%
EBIT margin	-82.1%	-52.6%	-44.2%	-45.3%
Interest income	1.1	2.3	1.9	1.9
Interest income	1.1	2.3	1.9	1.9
Other income (expense), net	11.4	28.3	9.9	10.9
Pre-tax income	-100.8	-26.3	-26.0	-26.0
Income taxes	0.4	0.3	-0.3	-0.3
Tax rate			1.1%	1.1%
Minority interest	-0.8	-2.2	-1.1	-1.1
Net income	-100.4	-24.5	-24.6	-25.7
Net margin	-72.8%	-22.6%	-28.7%	-30.0%

Basic EPS [+]	($1.42)	($0.41)	($4.09)	$0.00
Growth	248.9%	-90.0%	95577.7%
Diluted EPS [+]	($1.42)	($0.41)	($4.09)	$0.00
Growth	248.9%	-90.0%	95577.7%

Shares outstanding (basic) [+]	70.6	60.0	6.0	6,004.5
Growth	17.6%	899.7%	-99.9%
Shares outstanding (diluted) [+]	70.6	60.0	6.0	6,004.5
Growth	17.6%	899.7%	-99.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.